24-Apr-2026
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
PRNewswire (Fri, 24-Apr 10:24 AM ET)
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
PRNewswire (Thu, 23-Apr 8:30 AM ET)
PRNewswire (Thu, 9-Apr 8:01 AM ET)
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
PRNewswire (Thu, 2-Apr 8:01 AM ET)
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PRNewswire (Mon, 30-Mar 8:00 AM ET)
PRNewswire (Thu, 26-Mar 8:00 AM ET)
PRNewswire (Mon, 16-Mar 9:01 AM ET)
PRNewswire (Thu, 12-Mar 9:01 AM ET)
PAVmed Resets Capital Structure: $45 Million Financing Retires Legacy Convertible Securities
Market Chameleon (Wed, 4-Feb 3:49 AM ET)
PRNewswire (Wed, 4-Feb 8:01 AM ET)
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
Pavmed trades on the NASDAQ stock market under the symbol PAVM.
As of April 24, 2026, PAVM stock price declined to $9.00 with 13,892 million shares trading.
PAVM has a beta of 0.51, meaning it tends to be less sensitive to market movements. PAVM has a correlation of 0.01 to the broad based SPY ETF.
PAVM has a market cap of $8.29 million. This is considered a Sub-Micro Cap stock.
Last quarter Pavmed reported $52,000 in Revenue and -$1.05 earnings per share. This beat revenue expectation by $27,000 and exceeded earnings estimates by $3.57.
In the last 3 years, PAVM traded as high as $270.00 and as low as $6.00.
The top ETF exchange traded funds that PAVM belongs to (by Net Assets): VXF.
PAVM has underperformed the market in the last year with a price return of -60.2% while the SPY ETF gained +31.9%. PAVM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -1.7% and -2.6%, respectively, while the SPY returned +3.8% and +5.1%, respectively.
PAVM support price is $8.71 and resistance is $9.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PAVM shares will trade within this expected range on the day.
